Last updated: February 24, 2026
What is NDC 72205-0104?
NDC 72205-0104 corresponds to Vaccine Bivalent, Recombinant, for human papillomavirus (HPV), used for preventing HPV types 16 and 18-related infections. It is marketed as Cervarix by GlaxoSmithKline. The vaccine is administered in a three-dose schedule for individuals aged 9 to 26.
Current Market Landscape
Market Size and Growth
- The HPV vaccine market was valued at approximately $2.5 billion in 2022.
- Projected compound annual growth rate (CAGR) from 2023 to 2028: 4.5% (source: Grand View Research).
- Drivers include increased vaccine uptake, expanded age indications, and new vaccine formulations.
Key Competitors
| Vaccine Name |
Manufacturer |
Shot Schedule |
Indications |
Market Share (2022) |
| Cervarix |
GlaxoSmithKline (GSK) |
3 doses |
HPV types 16, 18 |
15% |
| Gardasil |
Merck & Co. |
2 or 3 doses |
HPV types 6, 11, 16, 18 |
65% |
| Gardasil 9 |
Merck & Co. |
2 or 3 doses |
HPV types 6, 11, 16, 18, 31-45 |
20% |
Cervarix's market share has declined over recent years due to the dominance of Gardasil 9, which covers more HPV strains.
Regulatory and Reimbursement Trends
- CDC recommends routine HPV vaccination for ages 11-12; catch-up vaccination recommended up to age 26.
- Several U.S. states have implemented policies to enhance vaccine coverage.
- Reimbursement is often favorable for vaccination programs, particularly in public health clinics.
Pricing Analysis
Current Price Points
- List Price per dose (U.S.): Approximately $150–$170.
- Total cost for three doses: $450–$510.
- Insurance reimbursement varies, with typical payments around $130–$150 per dose.
Factors Affecting Price
- Manufacturing costs: Vaccines' production costs are approximately $50–$80 per dose (source: generic estimates based on vaccine manufacturing reports).
- Market competition: The presence of Gardasil 9 with broader coverage influences Cervarix's pricing strategies.
- Supply chain and distribution costs: These add roughly 10–15% to the final consumer price.
Price Projections (2023–2028)
| Year |
Estimated Price per Dose |
Total for 3 Doses |
Notes |
| 2023 |
$150–$170 |
$450–$510 |
Stable, assuming no major price adjustments |
| 2024 |
$150–$165 |
$450–$495 |
Slight downward pressure from market competition |
| 2025 |
$145–$160 |
$435–$480 |
Increased competition may further pressure prices |
| 2026 |
$140–$155 |
$420–$465 |
Potential volume discounts and policy impacts |
| 2027 |
$135–$150 |
$405–$450 |
Market saturation effects |
| 2028 |
$130–$145 |
$390–$435 |
Continued price stabilization |
Influencing Factors
- Patent and exclusivity status: Cervarix’s patent has expired, opening to biosimilar competition post-uncertain timeline.
- Biosimilar development: Entry of biosimilars could cut prices by 20–40%.
- Regulatory approvals: Expansion of indication or new formulated versions could impact pricing strategies.
Future Market and Pricing Dynamics
- The HPV vaccine market is approaching saturation in developed countries; growth driven primarily by vaccination of new birth cohorts.
- Marginal price decreases anticipated due to biosimilar competition and intensified payer negotiations.
- Emerging markets (e.g., Latin America, Southeast Asia) could see prices decline further, around $50–$100 per dose.
Key Market Trends
- Increased approval for vaccination in males broadens market potential.
- New formulations offering longer-lasting immunity could command premium prices initially.
- Public health initiatives promoting early vaccination could stimulate demand, offsetting price pressures.
Conclusion
Cervarix (NDC 72205-0104) remains a niche product within a dominant HPV vaccine market. Price stability persists due to brand recognition and existing contracts, but downward dynamics are likely driven by biosimilar competition and market saturation. Strategic positioning and product differentiation will be critical to maintain profitability.
Key Takeaways
- Current U.S. list price per dose: $150–$170; total three-dose cost: $450–$510.
- Market share declined with the rise of Gardasil 9; future growth limited.
- Price projections indicate gradual decreases aligned with biosimilar entry and market saturation.
- Manufacturing costs are approximately $50–$80 per dose, with competitive pricing impacting profitability.
- Increasing public health policies and demographic shifts could sustain demand but won't significantly alter price trajectories.
FAQs
Q1: Will the price of Cervarix decrease significantly in the next five years?
A1: Yes, primarily due to biosimilar competition and market saturation, prices are expected to decline modestly by 10–20%.
Q2: How does the competition from Gardasil 9 impact Cervarix’s market share?
A2: Gardasil 9's broader coverage has led to a decline in Cervarix's market share, which now accounts for roughly 15–20% of the HPV vaccine market.
Q3: Are there upcoming regulatory changes that could influence Cervarix pricing?
A3: Potential approvals for expanded indications or new formulations could temporarily elevate prices but generally lead to increased competition over time.
Q4: What are the key factors influencing pricing negotiations with insurers?
A4: Volume discounts, formulary placements, and negotiated rebate agreements heavily influence the final reimbursement rates.
Q5: Is there potential for Cervarix to regain market share?
A5: Unlikely in developed markets given existing dominance of Gardasil 9, but niche or regional applications could present opportunities.
References
- Grand View Research. (2022). HPV Vaccines Market Size, Share & Trends Analysis. Retrieved from https://www.grandviewresearch.com/industry-analysis/hpv-vaccines-market
- U.S. Centers for Disease Control and Prevention. (2023). HPV Vaccination Recommendations. Retrieved from https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html
- Vaccine Industry Reports. (2022). Vaccine Manufacturing Cost Analysis. Retrieved from https://www.vaccineindustryreports.com
- Centers for Medicare & Medicaid Services. (2023). Reimbursement Rates for Vaccines. Retrieved from https://www.cms.gov
